Immuno-Biological Laboratories Co., Ltd.
4570.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥4 | ¥5 | ¥4 | ¥3 |
| - Cash | ¥1 | ¥1 | ¥1 | ¥1 |
| + Debt | ¥0 | ¥0 | ¥0 | ¥0 |
| Enterprise Value | ¥4 | ¥4 | ¥3 | ¥3 |
| Revenue | ¥1 | ¥1 | ¥1 | ¥1 |
| % Growth | 18.7% | 2.8% | 22.7% | – |
| Gross Profit | ¥1 | ¥1 | ¥1 | ¥0 |
| % Margin | 64.8% | 63.3% | 66.3% | 58.2% |
| EBITDA | ¥0 | ¥0 | -¥0 | -¥0 |
| % Margin | 23.4% | 15.7% | -41.8% | -38.5% |
| Net Income | ¥0 | ¥0 | -¥0 | -¥0 |
| % Margin | 25.7% | 22.9% | -36.5% | -40% |
| EPS Diluted | 26.74 | 20.05 | -31.11 | -27.78 |
| % Growth | 33.4% | 164.4% | -12% | – |
| Operating Cash Flow | ¥0 | ¥0 | ¥0 | -¥0 |
| Capital Expenditures | -¥0 | -¥0 | ¥0 | ¥0 |
| Free Cash Flow | ¥0 | ¥0 | ¥0 | -¥0 |